Janssen Research & Development, a division of Janssen Pharmaceutica NV and Proteros biostructures GmbH have announced that they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services.
Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and fully integrated structure-based lead discovery programs to identify small molecule inhibitors.
This is a consolidation of the services Proteros has provided over the past eight years in support of Janssen discovery research efforts in the USA and Europe.
Dr Torsten Neuefeind, Chief Executive Officer for Proteros commented “it is an important milestone for Proteros that the work performed by our scientists to support Janssen global discovery research is recognized as being of such high value that is has developed into this strategic collaboration. Proteros looks forward to contributing innovations and high quality science that makes a positive impact on Janssen’s research success”.